

### REMARKS

Claims 1, 2, 10-12 will be pending in the case. Claims 3-9 are withdrawn from consideration pursuant to the restriction requirement. Applicants expressly reserve the right pursue the subject matter of the withdrawn and canceled claims in another related application. Claims 10-12 are new, fall within Group I, and do not constitute new matter.

The Office Action sets forth a restriction requirement under 35 USC §121. Applicants were requested to elect one of six designated groups as briefly noted below:

I. Claims 1-2, drawn to a fusion protein comprising a first polypeptide of SEQ ID NO:2 and comprising a second cytokine polypeptide of SEQ ID NO:111, classified in class 530, subclass 350.

II. Claims 1-2, drawn to a fusion protein comprising a first polypeptide of SEQ ID NO:2 and comprising a second cytokine polypeptide of SEQ ID NO:112, classified in class 530, subclass 350.

III. Claims 1-2, drawn to a fusion protein comprising a first polypeptide of SEQ ID NO:2 and comprising a second cytokine polypeptide of SEQ ID NO:113, classified in class 530, subclass 350.

IV. Claims 1-2, drawn to a fusion protein comprising a first polypeptide of SEQ ID NO:2 and comprising a second cytokine polypeptide of SEQ ID NO:114, classified in class 530, subclass 350.

V. Claims 3-5, drawn to a fusion protein comprising four cytokine polypeptide fragments, classified in class 530, subclass 350.

VI. Claims 6-9, drawn to a fusion protein comprising a polypeptide of SEQ ID NO:2 and immunoglobulin heavy chain constant region, classified in class 530, subclass 350.

In response to the Requirement for Restriction Election, Applicants elect Group I drawn to a fusion protein comprising a first polypeptide of SEQ ID NO:2 and comprising a second cytokine polypeptide of SEQ ID NO:111, classified in class 530, subclass 350.

Applicants: Julia E. Novak et al.

Serial No.: 10/787,442

Filed: February 26, 2004

For: CYTOKINE ZALPHA11 LIGAND FUSION PROTEINS

---

Early consideration and allowance of the pending claims under examination are respectfully requested. If the Examiner believes that a telephone interview would expedite prosecution of the above-identified patent application, please call the undersigned at (206) 442-6672.

Respectfully Submitted,



Deborah A. Sawislak  
Registration No. 37,438

Customer No. 10117  
ZymoGenetics, Inc.  
1201 Eastlake Avenue East  
Seattle, Washington 98102